BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24474598)

  • 1. (18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer.
    Metser U; Rashidi F; Moshonov H; Wong R; Knox J; Guindi M; Darling G
    Ann Nucl Med; 2014 May; 28(4):295-303. PubMed ID: 24474598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of
    Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy.
    Chang S; Koo PJ; Kwak JJ; Kim SJ
    Oncology; 2016; 90(2):97-102. PubMed ID: 26771676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
    Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
    Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
    Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
    Cabral F; Cruz A; Casaca R; Monteiro C; Ramos P; Pedro C; Brandão F; Fonseca R; Ratão P; Salgado L; Pinto I; Abecasis N
    Cancer Radiother; 2020 Dec; 24(8):834-841. PubMed ID: 33191120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma.
    Fencl P; Belohlavek O; Harustiak T; Zemanova M
    Nucl Med Commun; 2012 Nov; 33(11):1188-94. PubMed ID: 22828453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
    Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
    PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients.
    Kim SJ; Koo PJ; Chang S
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):723-31. PubMed ID: 26891957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
    J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
    J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
    Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
    J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Lee SJ; Kim JG; Lee SW; Chae YS; Kang BW; Lee YJ; Park JS; Choi GS
    Cancer Chemother Pharmacol; 2013 May; 71(5):1201-7. PubMed ID: 23420438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.